Last quarter (Q3 2024), Zura Bio's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Zura Bio's net income was $-22.94M. See Zura Bio’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Mar 22	Dec 21
Total Revenue	$ ―	$ ―	$ ―	$ 0.00	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ 50.28M	$ 62.64M	$ 27.16M	$ 7.82M	$ 888.54K
Operating Income	$ -50.28M	$ -62.64M	$ -27.16M	$ -7.82M	$ -888.54K
Net Non Operating Interest Income Expense	$ 7.24M	$ 2.19M	$ -8.00K	$ ―	$ 51.00
Other Income Expense	$ 2.04M	$ -111.00K	$ -179.00K	$ ―	$ -11.28M
Pretax Income	$ -47.25M	$ -60.56M	$ -27.33M	$ -7.82M	$ 10.39M
Tax Provision	$ ―	$ ―	$ ―	$ ―	$ ―
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ -53.49M	$ -69.24M	$ -32.39M	$ -7.82M	$ 10.39M
Basic EPS	$ 1.71	$ -2.09	$ 0.21	$ -0.45	$ 1.24
Diluted EPS	$ 1.71	$ -2.09	$ 0.21	$ -0.45	$ 1.22
Basic Average Shares	$ 256.72M	$ 33.06M	$ 13.80M	$ 17.25M	$ 10.96M
Diluted Average Shares	$ 256.72M	$ 33.06M	$ 13.80M	$ 17.25M	$ 11.14M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 50.28M	$ 62.64M	$ 27.16M	$ 7.82M	$ 888.54K
Net Income From Continuing And Discontinued Operation	$ -47.24M	$ -60.36M	$ -25.74M	$ -7.82M	$ 6.85M
Normalized Income	$ -45.08M	$ -43.84M	$ ―	$ -7.82M	$ 8.21M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ -49.60M	$ -62.64M	$ -27.16M	$ -7.82M	$ 10.39M
EBITDA	$ -49.60M	$ -62.64M	$ -27.16M	$ -7.82M	$ 10.39M

Currency in USD

Zura Bio Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing